Integrated BioPharma (INBP) CFO awarded 140,000-share stock option at $0.31

Rhea-AI Filing Summary

Integrated BioPharma Inc. reported a new stock option grant to its Chief Financial Officer, Dina L. Masi. On 12/09/2025, she received an option to purchase 140,000 shares of the company’s common stock at an exercise price of $0.31 per share. The option has an expiration date of 12/09/2035, giving a long-term window to exercise.

The option vests in three equal annual installments, with the first installment becoming exercisable on December 9, 2026. This means the grant is designed as a multi-year incentive, aligning the CFO’s potential equity gains with the company’s performance over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Masi Dina

(Last) (First) (Middle)

14 LEXINGTON WAY

(Street)

LONG VALLEY NJ 07853

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRATED BIOPHARMA INC [ INBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.31	12/09/2025		A		140,000		(1)	12/09/2035	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 9, 2026.

	/s/ Dina L Masi	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Integrated BioPharma Inc. (INBP) disclose in this Form 4?

Integrated BioPharma Inc. disclosed that its Chief Financial Officer, Dina L. Masi, received a stock option grant for 140,000 shares of common stock at an exercise price of $0.31 per share on 12/09/2025.

Who is the reporting person in this INBP Form 4 filing and what is their role?

The reporting person is Dina L. Masi, who serves as the Chief Financial Officer of Integrated BioPharma Inc.

What are the key terms of the stock option granted to the INBP CFO?

The grant is a stock option for 140,000 shares of common stock at an exercise price of $0.31 per share, with an expiration date of 12/09/2035.

How does the stock option for the INBP CFO vest over time?

The option vests and becomes exercisable in three equal annual installments, with the first installment vesting on December 9, 2026.

Is the INBP CFO’s stock option held directly or indirectly?

The Form 4 reports that the 140,000 stock options are held with direct (D) ownership by Dina L. Masi.

What type of security underlies the INBP CFO’s stock option grant?

The derivative security is a stock option (right to buy), and the underlying security is common stock of Integrated BioPharma Inc., covering 140,000 shares.